1.12

1.75% -0.02

After Hours: 1.14 0.02 +1.79%

Akari Therapeutics Plc Adr (AKTX)

Overview News Price History Financials Discussions Forecast Stock Split

Akari Therapeutics Plc Adr stock is traded at $1.12, with a volume of 42,297. It is down -1.75% in the last 24 hours and down -52.63% over the past month. Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Previous Close:

$1.14

Open:

$1.12

24h Volume:

42,297

Relative Volume:

1.40

Market Cap:

$27.98M

Revenue:

Net Income/Loss:

P/E Ratio:

-3.2175

EPS:

-0.3481

Net Cash Flow:

1W Performance:

-23.81%

1M Performance:

-52.63%

6M Performance:

-42.56%

1Y Performance:

-61.51%

1-Day Range:

$1.06

$1.15

1-Week Range:

$0.90

$1.45

52-Week Range:

$0.90

$4.40

Akari Therapeutics Plc Adr Stock (AKTX) Company Profile

Name

Akari Therapeutics Plc Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(646) 350-0702

Address

22 BOSTON WHARF ROAD, BOSTON

Employee

Twitter

@AkariTX

Next Earnings Date

2024-04-29

Latest SEC Filings

AKTX's Discussions on Twitter

Compare AKTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKTX Akari Therapeutics Plc Adr	1.12	27.98M	0	0	0	-0.3481
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral
Apr-17-17	Reiterated	Chardan Capital Markets	Sell
Jul-11-16	Initiated	Chardan Capital Markets	Sell

View All

Akari Therapeutics Plc Adr Stock (AKTX) Latest News

Nov 19, 2024

Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan

Nov 19, 2024

Nov 14, 2024

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga

Nov 14, 2024

Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan

Nov 14, 2024

Nov 08, 2024

Akari Therapeutics shareholders approve Peak Bio merger - Investing.com

Nov 08, 2024

Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK

Nov 08, 2024

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan

Nov 08, 2024

Nov 01, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Nov 01, 2024

Oct 15, 2024

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan

Oct 15, 2024

Oct 04, 2024

Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 04, 2024

Sep 18, 2024